×

Goldman has a new favorite biotech because of potential Alzheimer's 'blockbuster'

10:46 AM ET Wed, 16 Aug 2017

Research analyst Terence Flynn added Biogen to Goldman Sachs' Americas Conviction List on optimism its Alzheimer's drug may be the first to successfully slow the progression of the disease.